These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


290 related items for PubMed ID: 16297803

  • 1. Combined administration of intravenous dipyridamole and inhaled nitric oxide to assess reversibility of pulmonary arterial hypertension in potential cardiac transplant recipients.
    Lepore JJ, Dec GW, Zapol WM, Bloch KD, Semigran MJ.
    J Heart Lung Transplant; 2005 Nov; 24(11):1950-6. PubMed ID: 16297803
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside.
    Kieler-Jensen N, Lundin S, Ricksten SE.
    J Heart Lung Transplant; 1995 Nov; 14(3):436-43. PubMed ID: 7654728
    [Abstract] [Full Text] [Related]

  • 5. Intravenous dipyridamole enhances the effects of inhaled nitric oxide and prevents rebound pulmonary hypertension in piglets.
    Foubert L, De Wolf D, Mareels K, Van Belleghem Y, Reyntjens K, Mortier E, Van Nooten G.
    Pediatr Res; 2002 Nov; 52(5):730-6. PubMed ID: 12409521
    [Abstract] [Full Text] [Related]

  • 6. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs.
    Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, Chang Y, Bloch KD, Zapol WM.
    Circulation; 2004 Oct 12; 110(15):2253-9. PubMed ID: 15466650
    [Abstract] [Full Text] [Related]

  • 7. Inhaled nitric oxide. Selective pulmonary vasodilation in cardiac surgical patients.
    Rich GF, Murphy GD, Roos CM, Johns RA.
    Anesthesiology; 1993 Jun 12; 78(6):1028-35. PubMed ID: 8512095
    [Abstract] [Full Text] [Related]

  • 8. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease.
    Schulze-Neick I, Hartenstein P, Li J, Stiller B, Nagdyman N, Hübler M, Butrous G, Petros A, Lange P, Redington AN.
    Circulation; 2003 Sep 09; 108 Suppl 1():II167-73. PubMed ID: 12970227
    [Abstract] [Full Text] [Related]

  • 9. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension.
    Givertz MM, Hare JM, Loh E, Gauthier DF, Colucci WS.
    J Am Coll Cardiol; 1996 Dec 09; 28(7):1775-80. PubMed ID: 8962566
    [Abstract] [Full Text] [Related]

  • 10. A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients.
    Khan TA, Schnickel G, Ross D, Bastani S, Laks H, Esmailian F, Marelli D, Beygui R, Shemin R, Watson L, Vartapetian I, Ardehali A.
    J Thorac Cardiovasc Surg; 2009 Dec 09; 138(6):1417-24. PubMed ID: 19931670
    [Abstract] [Full Text] [Related]

  • 11. Inhaled nitric oxide through a noninvasive ventilation device to assess reversibility of pulmonary hypertension in selecting recipients for heart transplant.
    Fojón S, Fernández-González C, Sánchez-Andrade J, López-Pérez JM, Hermida LF, Rodríguez JA, Juffé A.
    Transplant Proc; 2005 Nov 09; 37(9):4028-30. PubMed ID: 16386617
    [Abstract] [Full Text] [Related]

  • 12. Low doses of inhaled nitric oxide in heart transplant recipients.
    Auler Júnior JO, Carmona MJ, Bocchi EA, Bacal F, Fiorelli AI, Stolf NA, Jatene AD.
    J Heart Lung Transplant; 1996 May 09; 15(5):443-50. PubMed ID: 8771498
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of pulmonary vascular response to inhaled iloprost in heart transplant candidates with pulmonary venous hypertension.
    Braun S, Schrötter H, Schmeisser A, Strasser RH.
    Int J Cardiol; 2007 Jan 31; 115(1):67-72. PubMed ID: 16797747
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Inhaled aerosolized iloprost in the evaluation of heart transplant candidates--experiences with 45 cases.
    Sablotzki A, Hentschel T, Hofmann S, Simm A, Mühling J, Czeslick E.
    J Clin Anesth; 2006 Mar 31; 18(2):108-13. PubMed ID: 16563327
    [Abstract] [Full Text] [Related]

  • 16. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide.
    Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, Semigran MJ.
    Chest; 2005 May 31; 127(5):1647-53. PubMed ID: 15888841
    [Abstract] [Full Text] [Related]

  • 17. Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement.
    Fattouch K, Sbraga F, Bianco G, Speziale G, Gucciardo M, Sampognaro R, Ruvolo G.
    J Card Surg; 2005 May 31; 20(2):171-6. PubMed ID: 15725144
    [Abstract] [Full Text] [Related]

  • 18. Prostaglandin E1 testing in heart failure-associated pulmonary hypertension enables transplantation: the PROPHET study.
    von Scheidt W, Costard-Jaeckle A, Stempfle HU, Deng MC, Schwaab B, Haaff B, Naegele H, Mohacsi P, Trautnitz M, PROPHET Study Group.
    J Heart Lung Transplant; 2006 Sep 31; 25(9):1070-6. PubMed ID: 16962468
    [Abstract] [Full Text] [Related]

  • 19. Iloprost improves hemodynamics in patients with severe chronic cardiac failure and secondary pulmonary hypertension.
    Sablotzki A, Czeslick E, Schubert S, Friedrich I, Mühling J, Dehne MG, Grond S, Hentschel T.
    Can J Anaesth; 2002 Dec 31; 49(10):1076-80. PubMed ID: 12477682
    [Abstract] [Full Text] [Related]

  • 20. Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease.
    Yin N, Kaestle S, Yin J, Hentschel T, Pries AR, Kuppe H, Kuebler WM.
    Crit Care Med; 2009 Mar 31; 37(3):980-6. PubMed ID: 19237907
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 15.